Laurus Labs buys 60% of Canada's Galenvs for $3.75M to expand oligonucleotides
What's the deal? Laurus Labs has signed a definitive agreement to acquire a 60% stake in GalenvsDealroom has a profile for this one. Try Dealroom → Sciences, a Montréal-based specialist in oligonucleotide synthesis and magnetic nanoparticle technology, for $3.75 million. The deal, announced on October 29, 2026, values Galenvs at a pre-money $3.5 million.
What each side brings: Galenvs runs a vertically integrated platform covering discovery, synthesis, purification and pilot-scale production, and reported turnover of $1.6 million in 2025. Laurus, a contract development and manufacturing organisation (CDMO), adds large-scale manufacturing, complex chemistry and formulation.
How it's structured: The investment comes in two tranches — $2.75 million for 8 million new common shares and $1 million for 16% of post-issue equity. Galenvs will handle early-stage work and transfer technology to Laurus for later clinical phases and commercial scale-up.
Why now? Laurus is riding a strong quarter: Q2 FY27 revenue rose 33% year on year to US$299.6M, with CDMO revenue up 75%. The acquisition gives it a North American research foothold and a development-to-manufacturing pipeline for oligonucleotides.
What's the endgame? Founder and chief executive officer Satyanarayana Chava called the deal a "pivotal step" in building an integrated TIDES (oligonucleotide and peptide) platform. Separately, Laurus is acquiring a 52% stake in Hyderabad-based SI&C Resins for US$4.35M to bring peptide resin production in-house.
The signal: At $3.75 million, this is a modest, strategic buy rather than a capacity play. It reflects a wider push among Indian CDMOs to move up the value chain into complex therapeutics, where the payoff hinges on converting early-stage projects into manufacturing contracts.
Read more: investywise.com
Image credit: Generated with Gemini